ECIO Stockholm Highlights for Ablation Fanatics

ECIO 2023 Is upon us! Back by popular demand are the highlights for those of us who eat, drink, and sleep percutaneous tumor ablation. Below are the "cant-miss" sessions that you will find the most interesting

Of course, perhaps the most exciting thing (completely unbiased) at ECIO is the launch of CAS-One IR version 4.1 - driven by AI. This exciting new software release is designed to help you visualize patient anatomy, and add confidence to your treatments.

With automatic organ segmentation including critical structures, an AI-driven AblaSure quantitative margin assessment, and interactive planning mode, we have never been more confident in saying "more patients, better results".

Come by our booth, or check our our official page our official page

Now, for the scientific congress highlights - of notable mention are also 6 posters featuring CAS-One IR

Saturday April 15^th 

IOFC2 - Lung cancer and lung metastases
13:20-14:25 Auditorium 3 - Moderators: V. Grozman, O. Grundberg

• 2.1 Primary lung cancer types and overview of lung metastases - K. Dolapcsiev
• 2.2 Surgery: basic techniques and indications - E. Sachs
• 2.3 External radiotherapy and SBRT - D. Alm
• 2.4 Chemotherapy and immunotherapy - O. Grundberg
• 2.5 An outline of IO therapies and their roles in lung tumors - M. Beermann
  

Sunday April 16^th 

CF 111 - HCC: doubts we have brought with us to 2023
8:30-10:00 Auditorium 1 - Moderators: B. Sangro, P. Pereira

• 111.1 LIRADS: what are the pros and cons? - C. Aube
• 111.2 MALD-HCC: is it a completely different disease to handle? - M. Allaire
• 111.3 Is there space for improving the curative intent of ablation? - R. Iezzi
• 111.4 Has the perspective on the treatment of intermediate stage HCC changed? - I. Bargellini
• 111.5 Combining loco-regional treatments and immunotherapy: has the promise been kept? - J. Ricke
• 111.6 Systemic therapies for advanced HCC: success or failure? - B. Sangro

• 112.1 Head and neck tumour ablation - U. Pua
• 112.2 Thyroid: malignant lesions and recurrences - G. Mauri
• 112.3 Breast cancer - M. Tsitskari
• 112.4 Pancreas: intra-operative and percutaneous approaches - P. Peddu
• 112.5 Adrenal malignancies - G. Carrafiello
• 112.6 Prostate cancer - V. Ramalingam 

• 122.1 Stereotactic radiosurgery of bone metastases - M. Leu
• 122.2 Vertebral augmentation for cancer patients: which technique for which patient - S. Marcia
• 122.3 Palliative care in metastatic spinal and MSK tumours - R. Cazzato
• 122.4 Desmoids and desmoids fibromatosis - J. Garnon
• 122.5 Avoiding complications in osteoplasty techniques - S. Yevich
• 122.6 Neuroanatomy and thermoprotective techniques - A. Kurup 

• 141.1 RESPECT  - P. Wiggerman
• 141.2 SEASON HCC  - L. Crocetti
• 141.3 ZUGSPITZE - J. Ricke
• 141.4 HOLMBRAVE - L. Tselikas
• 141.5 - Study on vanishing lesions in the liver - final title to be announced - S. Holmin
• 141.6 - COVER-ALL - B. Odisio
• 141.7 DRAGON 2 - R. Korenblik
• 141.8 SIO Research grant program: experience from 5 grant cycles - J. Chapiro

Monday April 17^th 

• 211.1 Understanding the biology of mCRC: what defines oligometastatic disease - D. Arnold
• 211.2 New options of molecular determined treatment - G. Masi
• 211.3 Ablation: is there a maximum lesion size and number? - F. De Corbelli
• 211.4 Current position of TARE and TACE - S. White
• 211.5 ctDNA: a new instrument for surveillance after ablative treatment? K. Garm Spindler
• 211.6 Bridging CRC mets to liver transplantation - A. Vitale

• 222.1 Biomimetic thermochromic ablation phantoms to spatially inform immunogenic cell death and thermal stress - R. Morhard
• 222.2 A prospective multi-center trial on survival after microwave ablation versus resection for resectable colorectal liver metastases (MAVERRIC) - S. Ruiter
• 222.3 Primary tumor sidedness, RAS and BRAF mutations and MSI status as prognostic factors in patients with colorectal liver metastases treated with surgery and thermal ablation: results from the Amsterdam colorectal liver met registry (AmCORE) - H. Schulz
• 222.4 The role of intra-arterial 177Lu-Dotatate therapy in the treatment of hepatic metastases from neuroendrocrine tumors - V. Inampudi
• 222.5 Pancreatic cancer resistance features during irreversible electroporation (IRE) as a biomarker for the adaptive immune response and survival - F. Timmer

• 242.1 Resection in the solitary kidney setting - M. Tran
• 242.2 Ablation in the solitary kidney setting - A. King
• 242.3 Central renal cancer - F. Ridouani
• 242.4 Ablation in significant renal impairment: ever indicated? - C. Georgiades
• 242.5 T1b renal tumor ablation: is it time? - M. Calandri
• 242.6 Oligometastatic disease: role of IO - X. Buy

 Tuesday April 18^th 

• 322.1 Radiomics and genomics - F. Gomez Munoz
• 322.2 Segmentation and AI for treatment planning and procedural assistance - B. Meyer
• 322.3 AI and follow up of IO treatments - M. Maas
• 322.4 From diagrams to algorithms: AI in decision making - J. Chapiro
• 322.5 Augmented reality and AI in education and training in IO - M. Krokidis
• 322.6 Robotics for percutaneous approaches - P. Wiggerman

• 323.1 Combinatorial application of cryoablation and immunotherapies in melanoma - C. Yakkala
• 323.2 Use of renal tumour biopsy prior to nephrectomy - an analysis of the British Association of Urological surgeons nephrectomy outcome data from 2012-2019 - V. Chan
• 323.3 Volumetric assessment of the periablational safety margin after thermal ablation of colorectal liver metastases: a multicenter and intersoftware study - C. Overduin
• 323.4 What happens beyond one year following interventional ablation, cementoplasty, and screw fixation for periacetabular osteolytic metastases? F. Lee
• 323.5 The effect of age on overall survival after percutaneous cryoablation for stage I renal cell carcinoma
• 323.6 MR-guided stereotactic ablative radiotherapy versus percutaneous irreversible electroporation for the treatment of locally advanced pancreatic cancer (CROSSFIRE): a randomised phase 2/3 trial - F. Timmer
• 323.7 Minimally invasive nephron-sparing treatments for T1 renal cell cancer in patients over 75 years: a comparison of outcomes after robot-assisted partial nephrectomy and percutaneous ablation - R. Lehrer
• 323.8 Impact of ophthalmic artery chemo-infusion in the treatment of children with bilateral retinoblastoma - N Shetty
• 323.9 Deep learning-assisted ablative margin analysis for MR-guided prostate cryoablation: feasibility and initial retrospective validation - C. Overduin
• 323.10 Research in interventional oncology: how sound is the evidence base? - N. Kaufmann

• 342.1 Epidemiology and classification - N. Schaefer
• 342.2 Nuclear medicine diagnostic, follow-up and therapy - C. Hindorf
• 342.3 Systemic therapy: what's new - M. Pavel
• 342.4 Surgery: indications and limits for debulking purposes - T. Armstrong
• 342.5 Ablation: stand alone therapy and complement to surgery - R. Bale
• 342.6 Intraarterial therapies: palliative vs curative intent, how and when - D. Maiettini

• 351.1 Planning in radiation oncology - from Chinagraph pencils to supercomputers - L. Kenny
• 351.2 The importance of tumour margins in percutaneous ablation - C. Sofocleous
• 351.3 Percutaneous ablation: the role of planning and assessment software - L. Solbiati
• 351.4 Stereotactic percutaneous tumour ablation: a practical tool or a curiosity to be admired and ignored? - R. Bale

Wednesday April 19^th  

• 411.1 The ESMO perspective: guidelines 2023 - F. Martinelli
• 411.2 The ideal patient to treat: the surgeon - A. Fretland
• 411.3 The ideal patient to treat: the interventional oncologist: C. Sofocleous